ISC
  • #ISC23
  • Access Virtual Experience
  • Access ePosters
  • Privacy Policy
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Program
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Program
Resources
  • #ISC23
  • Access Virtual Experience
  • Access ePosters
  • Privacy Policy
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconYouTube iconPinterest iconLinkedIn icon
Mar 18th, 2021

Applying the guidelines for early management of acute ischemic stroke using case studies

Case studies test attendees' knowledge of guidelines update.


Isc21 Case Vignettes

The latest update of the ASA/AHA Guidelines for the Early Management of Acute Ischemic Stroke is still being embraced by clinicians wanting to provide current evidence-based care.

William Powers, MD, chair of neurology at the University of North Carolina School of Medicine in Chapel Hill co-moderated "Case Vignettes From the 2019 Update of the Guidelines for the Early Management of Acute Ischemic Stroke" on Thursday, March 18. (The entire program is available on demand for registered ISC attendees until April 16.)

The most appropriate treatment for patients who present with a mild second stroke is not always clear. Thrombolysis is the obvious answer, and the wrong one, said Edward Jauch, MD, chief of system research at Mission Health at the University of North Carolina in Asheville. The use of IV alteplase may be harmful in patients who have had a prior ischemic stroke within the last three months. Thrombectomy is the preferred approach.

The evidence for thrombolysis in patients who present soon after the onset of a first stroke symptom is strong. Although the attendee poll found many respondents opting for anticoagulation or intensive insulin for an 80-year-old woman presenting just 30 minutes after a witnessed stroke onset with an initial NIH Stroke Scale (NIHSS) of 7.

“Trials all the way back to the International Stroke Trial in 1997 show no benefit to urgent anticoagulation, and the SHINE trial in 2019 was stopped early due to no difference in functional outcomes with intensive insulin versus standard care,” said Andrew Southerland, MD, MSc FAHA, associate professor of neurology at the University of Virginia in Charlottesville.

He added that multiple trials published in 2020 and 2021 suggest it is not appropriate to forego thrombolysis in eligible patents, even if thrombectomy is being considered. 

Attendees were also unclear on the appropriate treatment for patients with minimal neurological deficits. Nearly two-thirds of attendees picked an inappropriate approach for a woman who presented with an NIHSS of 2.

Guidelines clearly state that thrombolysis should not be used in patients who can be treated within three hours of symptom onset who have an NIHSS of 5 or less,” said David Tirschwell, MD, MSc, medical director of comprehensive stroke care at the University of Washington Medicine Stroke Center in Seattle.  

Most attendees, 65%, chose antihypertensive treatment for the patient, who was admitted with blood pressure of 200/115. Guidelines warn that acute antihypertensive treatment is not helpful in preventing death or dependency in patients whose blood pressure is less than 220/120. 

Another popular, and inappropriate, approach involves ticagrelor. Guidelines clearly note that ticagrelor is not recommended over aspirin for the treatment of patients with minor stroke. Only 30% of attendees chose the appropriate treatment, dual antiplatelet therapy with clopidogrel and aspirin for 21 days. 

There is also strong evidence in patients with mild stroke who present long after the onset of symptoms. Only 5% of attendees correctly voted to treat a man admitted 21 hours after last known well and an NIHSS of 7 with aspirin and admit to the stroke unit. 

“We have strong evidence that aspirin, when used within 48 hours of stroke onset, is a powerful intervention,” said Alejandro Rabinstein, MD, fellow in critical care neurology at Mayo Clinic in Rochester, Minnesota. “The International Stroke Trial, and other trials, show that aspirin within the first 48 hours prevents 10 deaths or recurrent strokes per 1,000 patients during the first two to four weeks.” 

Interesting Stories
NeuroLogica brings you the next generation SmartMSU™
Sponsored by NeuroLogica
NeuroLogica brings you the next generation SmartMSU™
Venous outflow and parenchymal hemorrhage: A clogged drain problem?
Sponsored by American Heart Association/American Stroke Association
Venous outflow and parenchymal hemorrhage: A clogged drain problem?
Telehealth after stroke care pilot randomized trial...
Sponsored by American Heart Association/American Stroke Association
Telehealth after stroke care pilot randomized trial...
ISC23 Welcome Guide
Sponsored by Microvention
ISC23 Welcome Guide
More Content
ISC21
State-of-the-Science Stroke Nursing Symposium
Register Now
Dec 6th, 2021
ISC21
AHA Professional Membership
Dec 6th, 2021
Getty Images 1170749170
ISC21
We want your feedback about #ISC22
Survey
Sep 20th, 2021
ISC21
Accessibility Statement
Sep 16th, 2021
Getty Images 1292736582
ISC21
Late-Breaking Science: New data in clot removal, stroke patients with COVID-19
Mar 19th, 2021
Getty Images 1178124559
ISC21
Debate: Optimal management for unruptured brain aneurysms
Mar 18th, 2021
Getty Images 1279891643
ISC21
Session highlights uncertainties in preventing stroke in COVID-19 patients
Mar 19th, 2021
Getty Images 1223133003
ISC21
Big data takes on stroke by the numbers
Mar 19th, 2021
Angels Partner Getty Images 1281414200
ISC21
ASA forms new partnership
Mar 19th, 2021
Academy Getty Images 1296726595
ISC21
Coming soon: AHA’s new health care education solution
Mar 19th, 2021
Maxresdefault 6054adb57d3ed
ISC21
Roos: MR CLEAN-NO IV results
Mar 19th, 2021
Maxresdefault 6054ab864857f
ISC21
Nogueira: SHRINE results
Mar 19th, 2021